Effects of Danggui Buxue Decoction on Cancer-related Fatigue in Patients with Anemia Undergoing Chemotherapy after Colon Cancer Operation: A Randomized Controlled Trial

Influence of Danggui Buxue Recipe on Cancer-related Fatigue Patients in on Digestive Tumor

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR2200005659

Enrollment

Unknown

Registered

2022-02-24

Start date

2022-03-01

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colon cancer

Interventions

Usual care group:Routine nursing

Danggui Buxue Decoction group:Routine nursing + Danggui Buxue Decoction

0201

Eligibility

Sex/Gender

All

Age

45 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Meet the diagnostic criteria for colon cancer and CRF before the intervention (2) Age 45-75 years old (3) Patients with mild to moderate anemia (According to the NCI standard, the Hb < 100g /L (4) Moderate to severe fatigue (with BFI-C score = 4) after cancer diagnosis due to cancer therapy or cancer itself (5) After receiving the first course of postoperative chemotherapy, the surgical procedure is not limited except for colostomy, and chemotherapy options are not limited (6) The patient has no mental illness, no communication barriers, and can independently complete the questionnaire survey (7) Sign the informed consent form and participate in this study, with good compliance (8) The KPS score is greater than 60 points

Exclusion criteria

Exclusion criteria: (1) Severe trauma, complicated and difficult major surgery or after intestinal stoma (2) The spirit, intelligence, or thinking is abnormal and unable to cooperate (3) Abnormal findings in a liver function test or a renal function test (aspartate aminotransferase or alanine aminotransferase = 2× upper normal range or creatinine = 2.0 mg/dL) or the presence of serious liver failure or renal failure (4) Measures to relieve fatigue, such as cognitive behavioral therapy, psychosocial intervention, regular aerobic exercise (a regular moderate-intensity aerobic exercise time per week 5.1µIU/ml (7) History of medication (methylphenidate, modafinil, bupropion, dexamethasone) to manage cancerrelated fatigue taken within 4 weeks of the beginning of the trial (8) Having participated in other clinical trials after the beginning of the trial

Design outcomes

Primary

Measure	Time frame
EORTC QLQ-C30;The Chinese version of the Brief Fatigue Inventory (BFI-C);	—

Secondary

Measure	Time frame
Adverse events;The Fuzhou version of the Montreal Cognitive Assessment (MoCA-fuzhou);Laboratory examination;TCM syndrome scores;	—

Countries

China

Contacts

Public ContactYang Liu

94493607@qq.com+8613959148480

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026